抗炎肽Ac-SDKP：合成，在ACE抑制中的作用及其在高血压和心血管疾病中的治疗潜力。,Pharmacological Research

当前位置： X-MOL 学术 › Pharmacol. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

抗炎肽Ac-SDKP：合成，在ACE抑制中的作用及其在高血压和心血管疾病中的治疗潜力。
Pharmacological Research ( IF 9.1 ) Pub Date : 2018-07-11 , DOI: 10.1016/j.phrs.2018.07.006
Nitin Kumar ₁ , Congcong Yin ₂

Affiliation

心血管疾病（CVD）约占全球所有死亡人数的31％，仅高血压就占这些病例的约50％。心脏，肾脏和脑部的炎症和随后的纤维化与CVD患者的发病率和死亡率增加有关。N-乙酰基-Seryl-天冬氨酰-脯氨酸（Ac-SDKP）是一种天然存在的免疫调节和促血管生成肽，主要通过其前体胸腺素β4（Tβ4）通过涉及meprin-α和脯氨酰-寡肽酶的酶水解而释放，而Ac-SDKP降解主要通过血管紧张素转化酶（ACE）进行。考虑到其免疫调节和血管生成特性，许多研究集中于其在心血管疾病中的有益作用。在过去20年中，涉及心脏，肾脏和脑部损伤的研究表明，Ac-SDKP的治疗可以通过减少炎症，纤维化和促进血管生成来部分缓解终末器官损伤。涉及ACE抑制剂治疗的临床研究表明，血浆和组织中的Ac-SDKP浓度增加，而ACE抑制剂对高血压的某些有益作用部分是由于Ac-SDKP含量增加。有趣的是，Ac-SDKP的这些保护作用与血压调节无关。这篇综述讨论了健康和疾病条件下的Ac-SDKP生物学，确定了其可能的作用机理，并探讨了Ac-SDKP作为CVD的新疗法的潜在用途。ACE抑制剂对高血压的一些有益作用部分是由于Ac-SDKP含量的增加。有趣的是，Ac-SDKP的这些保护作用与血压调节无关。这篇综述讨论了健康和疾病条件下的Ac-SDKP生物学，确定了其可能的作用机理，并探讨了Ac-SDKP作为CVD的新疗法的潜在用途。ACE抑制剂对高血压的一些有益作用部分是由于Ac-SDKP含量的增加。有趣的是，Ac-SDKP的这些保护作用与血压调节无关。这篇综述讨论了健康和疾病条件下的Ac-SDKP生物学，确定了其可能的作用机理，并探讨了Ac-SDKP作为CVD的新疗法的潜在用途。

"点击查看英文标题和摘要"

The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases.

Cardiovascular diseases (CVDs) represent ∼31% of all global deaths, and hypertension alone accounts for ∼50% of these cases. Inflammation and subsequent fibrosis in heart, kidney and brain are associated with increased morbidity and mortality in CVD patients. N-Acetyl-Seryl-Aspartyl-Proline (Ac-SDKP) is a naturally occurring immunomodulatory and pro-angiogenic peptide mainly released from its precursor thymosin β4 (Tβ4) via enzymatic hydrolysis involving meprin-α and prolyl-oligopeptidase, while Ac-SDKP degradation is primarily carried out by angiotensin converting enzyme (ACE). Keeping its immunomodulatory and angiogenic properties in view, numerous studies have focused on its beneficial effects in cardiovascular diseases. Research in the past 20 years involving heart, kidney and brain injury show that, treatment with Ac-SDKP ameliorates end-organ damage in part, by reducing inflammation, fibrosis and by promoting angiogenesis. Clinical studies involving ACE inhibitor therapy have shown increased plasma and tissue Ac-SDKP concentration, and some of the beneficial effects of ACE inhibitors in hypertension are partly due to increased Ac-SDKP content. Interestingly, these protective effects of Ac-SDKP are independent of blood-pressure regulation. This review discusses the Ac-SDKP biology in health and disease conditions, identifying its possible mechanisms of action, and explore potential use of Ac-SDKP as a novel treatment for CVDs.

更新日期：2019-11-01

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南